论文部分内容阅读
目的:观察人非小细胞肺癌(NSCLC)组织中CD137L的表达,探讨CD137L与NSCLC临床病理参数和预后的关系。方法:采用免疫组织化学技术分析61例NSCLC组织中CD137L的表达。将免疫组化检测结果与患者的临床病理特征以及生存时间进行统计学分析。结果:CD137L阳性表达定位于细胞质,部分位于细胞核。在NSCLC组织中的阳性表达率为45.90%(28/61),统计学分析显示,NSCLC组织CD137L表达与年龄、性别和病理类型等无明显相关性(P>0.05),而与临床分期相关(P=0.027),且CD137L表达阳性患者生存期较表达阴性患者延长,P=0.023。结论:CD137L在NSCLC组织中有表达,其阳性表达率可能与临床分期相关;CD137L阳性表达与患者预后呈正相关,对判断NSCLC的预后有一定的参考价值。
Objective: To observe the expression of CD137L in human non-small cell lung cancer (NSCLC) and to investigate the relationship between CD137L and clinicopathological parameters and prognosis of NSCLC. Methods: Immunohistochemistry was used to analyze the expression of CD137L in 61 NSCLC tissues. The results of immunohistochemistry and clinical pathological features and survival time of patients were statistically analyzed. Results: The positive expression of CD137L was localized in the cytoplasm and partly in the nucleus. The positive expression rate in NSCLC tissues was 45.90% (28/61). Statistical analysis showed that the expression of CD137L in NSCLC tissues was not significantly related to age, gender, pathological type (P>0.05), but related to clinical stage ( P=0.027), and the survival of CD137L-positive patients was longer than that of negative patients, P=0.023. Conclusion: CD137L is expressed in NSCLC tissues. The positive expression rate of CD137L may be related to the clinical stage. The positive expression of CD137L is positively correlated with the prognosis of patients. It has a certain reference value for the prognosis of NSCLC.